Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COXFA4 | O00483 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874660 | 1.00 | COXFA4 (0.53) | COXFA4BACE1ALDH1A1HPGDMEN1 | |
| SCHEMBL6648245 | 0.87 | ALDH1A1 (0.57) | COXFA4BACE1ALDH1A1HPGDMEN1 | |
| SCHEMBL6271732 | 0.85 | COXFA4 (0.49) | COXFA4BACE1ALDH1A1HPGDMEN1 | |
| SCHEMBL482234 | 0.85 | COXFA4 (0.49) | COXFA4ALDH1A1HPGDCYP3A4TDP1 | |
| SCHEMBL11398330 | 0.83 | COXFA4 (0.62) | COXFA4ALDH1A1HPGDCYP3A4TDP1 | |
| SCHEMBL14541271 | 0.82 | COXFA4 (0.52) | COXFA4BACE1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL7766618 | 0.82 | COXFA4 (0.49) | COXFA4BACE1ALDH1A1HPGDMEN1 | |
| SCHEMBL16865499 | 0.81 | COXFA4 (0.48) | COXFA4BACE1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL13689961 | 0.81 | COXFA4 (0.47) | COXFA4BACE1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL482313 | 0.80 | COXFA4 (0.50) | COXFA4ALDH1A1HPGDCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024248173-A1 | NOVEL STRAIN OF LYMOSILACTOBACILLUS SP. AND FOOD COMPOSITION FOR IMPROVING ANTIOXIDANT OR ANTI-STRESS FUNCTION COMPRISING FERMENTED RICE EXTRACT USING SAME | 주식회사 퓨처에프바이오텍 | 2024-12-05 | — | — | WO | disclosed |
| CN-117946055-A | Chromene aryl hydrazide derivative and preparation method and application thereof | 贵州医科大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117887835-A | Application of microbial flora and metabolites thereof in pulmonary fibrosis detection and/or preparation of medicines | 江西省胸科医院(江西省第三人民医院) | 2024-04-16 | — | — | CN | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| US-6090389-A | Method and preparations for the treatment of fungus | CHEN YU (US) | 2000-07-18 | — | — | US | disclosed |
| US-5837254-A | Method of treating candida and cryptococcus fungal infections by administering gentian | CHEN YU (US) | 1998-11-17 | — | — | US | disclosed |
| US-5656656-A | Tartronic acids, their acetalic ethers and O-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1997-08-12 | — | — | US | disclosed |
| EP-0690855-B1 | BENZOPYRANES AS POTASSIUM CHANNEL OPENERS | PFIZER LTD (GB) | 1996-12-18 | — | — | EP | disclosed |
| WO-1994020491-A1 | BENZOPYRANES AS POTASSIUM CHANNEL OPENERS | PFIZER LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HIF1AN | COXFA4 3510/4885BACE1 4475/4885ALDH1A1 355/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | COXFA4 3670/4885BACE1 4525/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.